Associative Peripheral Stimulation for Reduction of Motor Impairment During Acute Period of Stroke Recovery

Launched by AHMED A. RAHIM · Aug 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Associative Peripheral Stimulation (APS) to help improve movement and reduce weakness in the arms of stroke patients during their early recovery. APS uses a gentle electrical stimulation on the muscles while the patient tries to move their arm, which may help them regain strength and function in their affected upper limb. This study is currently looking for participants who have had a stroke within the last week and are experiencing weakness in one arm.

To be eligible for the trial, participants should be between the ages of 65 and 85 and must be able to understand and follow instructions. They also need to be able to move their fingers slightly on their own. Those with certain other medical conditions or previous upper-body disabilities may not qualify. If you decide to participate, you can expect to use this new therapy in a safe environment, and there will be regular follow-ups to monitor your progress. This study aims to find out if this approach can make a real difference in recovery after a stroke.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Confirmed ischemic or hemorrhagic stroke no earlier than 7 days prior to enrollment;
• • 2. Presentation of hemiparesis or paralysis of the upper extremity due to stroke;
• • 3. Ability to comprehend and follow study instructions;
• • 4. Ability to initiate finger extension (≥3°) at least three times per minute;
• • 5. Fugl-Meyer Assessment (Upper Extremity) score of \<47.
• Exclusion Criteria:
• • 1. Contraindications, intolerance, or high sensitivity to the experimental protocol;
• • 2. History of upper-extremity disability prior to the index stroke;
• • 3. Neurological conditions (other than stroke) affecting motor function;
• • 4. Treatment of spasticity/increased tone in the affected upper extremity (e.g., with Botox injection);
• • 5. Lack of access to a safe and suitable place of discharge for experimental sessions and follow-up visits.